Effect and Mechanism of Probiotics in Alleviating or Treating Inflammatory Bowel Disease

XU Kang; WANG Zhe; XUE Zhipeng; WANG Jiapeng; XU Zhenshang; WANG Ting

doi:10.13386/j.issn1002-0306.2021090166

Volume 43 Issue 20

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2022 > 43(20): 414-420. > DOI: 10.13386/j.issn1002-0306.2021090166

XU Kang, WANG Zhe, XUE Zhipeng, et al. Effect and Mechanism of Probiotics in Alleviating or Treating Inflammatory Bowel Disease[J]. Science and Technology of Food Industry, 2022, 43(20): 414−420. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2021090166.

Citation:

PDF (2021 KB)

Effect and Mechanism of Probiotics in Alleviating or Treating Inflammatory Bowel Disease

School of Biological Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China

More Information

Received Date: September 13, 2021
Available Online: August 03, 2022

Graphical Abstract

Abstract

Abstract

Inflammatory bowel disease (IBD), gradually increasing in China, is a chronic and recurrent intestinal inflammatory disease. Recently, probiotics have been applied for the treatment of IBD, and some probiotic strains can alleviate or treat IBD by protection of the intestinal barrier and regulating expression of immune and inflammatory factors. Meanwhile, probiotics have the characteristics of good tolerability and few adverse reactions, resulting in their commonness in the clinical application of IBD treatment. This article mainly introduces the research progress of probiotics in the treatment of IBD, including the classification, mechanism of action and clinical research.
- probiotics,
- inflammatory bowel disease(IBD),
- mechanism,
- clinical research

FullText(HTML)

References (50)

References

[1]	ZHANG Y Z, LI Y Y. Inflammatory bowel disease: Pathogenesis[J]. World Journal of Gastroenterology,2014,20(1):91−99. doi: 10.3748/wjg.v20.i1.91
[2]	NA S Y, MOON W. Perspectives on current and novel treatments for inflammatory bowel disease[J]. Gut and Liver,2019,13(6):604−616. doi: 10.5009/gnl19019
[3]	HILL C, GUARNER F, REID G, et al. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nature Reviews Gastroenterology & Hepatology,2014,11(8):506−514.
[4]	BOIRIVANT M, STROBER W. The mechanism of action of probiotics[J]. Current Opinion in Gastroenterology,2007,23(6):679−692. doi: 10.1097/MOG.0b013e3282f0cffc
[5]	GUANDALINI S, SANSOTTA N. Probiotics in the treatment of inflammatory bowel disease[J]. Advances in Experimental Medicine and Biology,2019,1125:101−107.
[6]	LIU Y W, SU Y W, ONG W K, et al. Oral administration of Lactobacillus plantarum K68 ameliorates DSS-induced ulcerative colitis in BALB/c mice via the anti-inflammatory and immunomodulatory activities[J]. International Immunopharmacology,2011,11(12):2159−2166. doi: 10.1016/j.intimp.2011.09.013
[7]	SUN M, LIU Y, SONG Y, et al. The ameliorative effect of Lactobacillus plantarum-12 on DSS-induced murine colitis[J]. Food & Function,2020,11(6):5205−5222.
[8]	CHUNG Y W, CHOI J H, OH T Y, et al. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice[J]. Clinical and Experimental Immunology,2008,151(1):182−189.
[9]	GHASEMI-NIRI S F, ABDOLGHAFFARI A H, FALLAH-BENAKOHAL S, et al. On the benefit of whey-cultured Lactobacillus casei in murine colitis[J]. Journal of Physiology and Pharmacology,2011,62(3):341−346.
[10]	CHEN C L, HSU P Y, PAN T M. Therapeutic effects of Lactobacillus paracasei subsp.paracasei NTU 101 powder on dextran sulfate sodium-induced colitis in mice[J]. Journal of Food and Drug Analysis,2019,27(1):83−92. doi: 10.1016/j.jfda.2018.05.004
[11]	SCHREIBER O, PETERSSON J, PHILLIPSON M, et al. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte- and platelet-endothelial cell interactions[J]. American Journal of Physiology Gastrointestinal and Liver Physiology,2009,296(3):G534−G542. doi: 10.1152/ajpgi.90470.2008
[12]	MIYAUCHI E, MORITA H, TANABE S. Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo[J]. Journal of Dairy Science,2009,92(6):2400−2408. doi: 10.3168/jds.2008-1698
[13]	JO S G, NOH E J, LEE J Y, et al. Lactobacillus curvatus WiKim38 isolated from kimchi induces IL-10 production in dendritic cells and alleviates DSS-induced colitis in mice[J]. Journal of Microbiology,2016,54(7):503−509. doi: 10.1007/s12275-016-6160-2
[14]	CHAUHAN R, VASANTHAKUMARI A S, PANWAR H, et al. Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1[J]. BioMed Research International,2014,2014(3):206732.
[15]	IZUMI H, MINEGISHI M, SATO Y, et al. Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats[J]. Pediatric Research,2015,78(4):407−416. doi: 10.1038/pr.2015.115
[16]	SRUTKOVA D, SCHWARZER M, HUDCOVIC T, et al. Bifidobacterium longum CCM 7952 promotes epithelial barrier function and prevents acute DSS-induced colitis in strictly strain-specific manner[J]. PloS One,2015,10(7):e0134050. doi: 10.1371/journal.pone.0134050
[17]	MIYAUCHI E, OGITA T, MIYAMOTO J, et al. Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: Involvement of intestinal epithelial costimulatory molecules[J]. PloS one,2013,8(11):e79735. doi: 10.1371/journal.pone.0079735
[18]	OGITA T, NAKASHIMA M, MORITA H, et al. Streptococcus thermophilus ST28 ameliorates colitis in mice partially by suppression of inflammatory Th17 cells[J]. Journal of biomedicine & biotechnology,2011,2011:378417.
[19]	BAILEY J R, VINCE V, WILLIAMS N A, et al. Streptococcus thermophilus NCIMB 41856 ameliorates signs of colitis in an animal model of inflammatory bowel disease[J]. Beneficial microbes,2017,8(4):605−614. doi: 10.3920/BM2016.0110
[20]	CHEN Y, ZHANG M, REN F. A Role of exopolysaccharide produced by Streptococcus thermophilus in the intestinal inflammation and mucosal barrier in Caco-2 monolayer and dextran sulphate sodium-induced experimental murine colitis[J]. Molecules,2019,24(3):513. doi: 10.3390/molecules24030513
[21]	IM E, CHOI Y J, POTHOULAKIS C, et al. Bacillus polyfermenticus ameliorates colonic inflammation by promoting cytoprotective effects in colitic mice[J]. The Journal of Nutrition,2009,139(10):1848−1854. doi: 10.3945/jn.109.108613
[22]	ZHANG H L, LI W S, XU D N, et al. Mucosa-reparing and microbiota-balancing therapeutic effect of Bacillus subtilis alleviates dextrate sulfate sodium-induced ulcerative colitis in mice[J]. Experimental and Therapeutic Medicine,2016,12(4):2554−2562. doi: 10.3892/etm.2016.3686
[23]	CAO G T, WANG K L, LI Z M, et al. Bacillus amyloliquefaciens ameliorates dextran sulfate sodium-induced colitis by improving gut microbial dysbiosis in mice model[J]. Frontiers in Microbiology,2019,9:3260. doi: 10.3389/fmicb.2018.03260
[24]	KANDA T, NISHIDA A, OHNO M, et al. Enterococcus durans TN-3 induces regulatory T cells and suppresses the development of dextran sulfate sodium (DSS)-induced experimental colitis[J]. PloS One,2016,11(7):e0159705. doi: 10.1371/journal.pone.0159705
[25]	CHOI E J, LEE H J, KIM W J, et al. Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model[J]. PloS One,2019,14(2):e0210854. doi: 10.1371/journal.pone.0210854
[26]	SOUZA É L, ELIAN S D, PAULA L M, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model[J]. Journal of Medical Microbiology,2016,65(3):201−210. doi: 10.1099/jmm.0.000222
[27]	LU J B, DONG B Y, CHEN A L, et al. Escherichia coli promotes DSS-induced murine colitis recovery through activation of the TLR4/NF-κB signaling pathway[J]. Molecular Medicine Reports,2019,19(3):2021−2028.
[28]	ZHANG M M, QIU X Y, ZHANG H, et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats[J]. PloS One,2014,9(10):e109146. doi: 10.1371/journal.pone.0109146
[29]	GANJI-ARJENAKI M, RAFIEIAN-KOPAEI M. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review[J]. Journal of Cellular Physiology,2018,233(3):2091−2103. doi: 10.1002/jcp.25911
[30]	REMBACKEN B J, SNELLING A M, HAWKEY P M, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial[J]. Lancet,1999,354(9179):635−639. doi: 10.1016/S0140-6736(98)06343-0
[31]	TAMAKI H, NAKASE H, INOUE S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial[J]. Digestive Endoscopy:Official Journal of the Japan Gastroenterological Endoscopy Society,2016,28(1):67−74.
[32]	ZOCCO M A, DAL VERME L Z, CREMONINI F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis[J]. Alimentary Pharmacology & Therapeutics,2006,23(11):1567−1574.
[33]	OLIVA S, DI NARDO G, FERRARI F, et al. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis[J]. Alimentary Pharmacology & Therapeutics,2012,35(3):327−334.
[34]	SOOD A, MIDHA V, MAKHARIA G K, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis[J]. Clinical Gastroenterology and Hepatology,2009,7(11):1202−1209. doi: 10.1016/j.cgh.2009.07.016
[35]	ISHIKAWA H, AKEDO I, UMESAKI Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis[J]. Journal of the American College of Nutrition,2003,22(1):56−63. doi: 10.1080/07315724.2003.10719276
[36]	BOUSVAROS A, GUANDALINI S, BALDASSANO R N, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease[J]. Inflammatory Bowel Diseases,2005,11(9):833−839. doi: 10.1097/01.MIB.0000175905.00212.2c
[37]	BOURREILLE A, CADIOT G, LE DREAU G, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease[J]. Clinical gastroenterology and hepatology:The Official Clinical Practice Journal of the American Gastroenterological Association,2013,11(8):982−987. doi: 10.1016/j.cgh.2013.02.021
[38]	MARTEAU P, LéMANN M, SEKSIK P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial[J]. Gut,2006,55(6):842−847. doi: 10.1136/gut.2005.076604
[39]	LIU X J, YU R, ZOU K F. Probiotic mixture VSL#3 alleviates dextran sulfate sodium-induced colitis in mice by downregulating T follicular helper cells[J]. Current medical science,2019,39(3):371−378. doi: 10.1007/s11596-019-2045-z
[40]	TOUMI R, ABDELOUHAB K, RAFA H, et al. Beneficial role of the probiotic mixture ultrabiotique on maintaining the integrity of intestinal mucosal barrier in DSS-induced experimental colitis[J]. Immunopharmacology and immunotoxicology,2013,35(3):403−409. doi: 10.3109/08923973.2013.790413
[41]	王彦博. 功能各异的益生菌复合缓解DSS诱导的溃疡性结肠炎机制研究 [D]. 吉林: 吉林大学, 2020. WANG Y B. Study on the mechanism of compound probiotics with different functions to relieve DSS-induced ulcerative colitis[D]. Jilin: Jilin University, 2020.
[42]	YOSHIMATSU Y, YAMADA A, FURUKAWA R, et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis[J]. World Journal of Gastroenterology,2015,21(19):5985−5994. doi: 10.3748/wjg.v21.i19.5985
[43]	SARAO L K, ARORA M. Probiotics, prebiotics, and microencapsulation: A review[J]. Critical Reviews in Food Science and Nutrition,2017,57(2):344−371. doi: 10.1080/10408398.2014.887055
[44]	李东尧. 低聚糖对肠道轴向微生物代谢功能的影响及机制 [D]. 无锡: 江南大学, 2020. LI D Y. The effect and mechanism of oligosaccharides on intestinal axial microbial metabolism[D]. Wuxi: Jiangnan University, 2020.
[45]	WASILEWSKI A, ZIELIŃSKA M, STORR M, et al. Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease[J]. Inflammatory bowel diseases,2015,21(7):1674−1682. doi: 10.1097/MIB.0000000000000364
[46]	HIJOVÁ E, ŠOLTÉSOVÁ A, SALAJ R, et al. Preventive use of Lactobacillus plantarum LS/07 and inulin to relieve symptoms of acute colitis[J]. Acta Biochimica Polonica,2015,62(3):553−557. doi: 10.18388/abp.2015_1008
[47]	王亚楠, 孟祥辰, 王春赛尔, 等. 益生菌和合生元对急性结肠炎小鼠肠道炎症及微生物群的影响[J]. 中华内科杂志,2019,58(8):584−591. [WANG Y N, MENG X C, WANG C S E, et al. The influence of probiotics and synbiotics on intestinal inflammation and microbiota in mice with acute colitis[J]. Zhonghua Nei Ke Za Zhi,2019,58(8):584−591.
[48]	ISHIKAWA H, MATSUMOTO S, OHASHI Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study[J]. Digestion,2011,84(2):128−133. doi: 10.1159/000322977
[49]	FUJIMORI S, GUDIS K, MITSUI K, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis[J]. Nutrition,2009,25(5):520−525. doi: 10.1016/j.nut.2008.11.017
[50]	郭宇冰, 王晓娜, 刘欣, 等. 肠道菌群与炎症性肠病关系的研究现状[J]. 结直肠肛门外科,2020,26(4):402−406,422. [GUO Yubing, WANG Xiaona, LIU Xin, et al. Research status of the relationship between intestinal flora and inflammatory bowel disease[J]. Colorectal and Anal Surgery,2020,26(4):402−406,422. doi: 10.19668/j.cnki.issn1674-0491.2020.04.003

Supplements (0)

Cited By

Cited by

Periodical cited type(26)

1.	郭莉滨. “双碳”和“健康中国”背景下植物基肉制品的营养组分及健康功能性研究进展. 食品安全质量检测学报. 2025(03): 123-129 .
2.	陈金换，安红周，孙嘉瑜，张皓冰，黄泽华. 植物蛋白的改性加工及热点应用领域研究进展. 粮油食品科技. 2025(02): 83-89 .
3.	王庆沛，宇光海，廖爱美，潘龙，黄继红. 微生物合成血红蛋白的研究进展及其在食品中的应用. 中国调味品. 2024(01): 189-197 .
4.	王彦丽，刘萌，朱来景，赵祥忠. 辣椒添加对植物蛋白肉感官特性的影响. 中国调味品. 2024(03): 28-32 .
5.	刘静，金娜，石春芹，李永双，邓清升，罗旋飞，刘艳，杨宝君，聂龙. 响应面法优化豌豆蛋白植物肉配方及其体外消化分析. 食品工业科技. 2024(08): 216-226 . 本站查看
6.	芦鑫，路风银，孙强，宋国辉，黄纪念. 植物蛋白肉感官品质与营养安全研究进展. 粮食与油脂. 2024(06): 6-10 .
7.	俎新宇，赵亚男，王新新，杨进洁，边文洁，赵祥忠，梁艳. DHA藻油微胶囊粉对植物蛋白肉品质特性的影响. 食品研究与开发. 2024(14): 23-29 .
8.	周鑫，马宁，王鑫，王恰，刘业学，田晓静，王稳航. 大豆组织蛋白发酵产品的体外消化特性. 食品研究与开发. 2024(17): 59-65 .
9.	麻梦寒，冯朵，李梦洁，李琥，郭丽萍，王靖. 植物基食品加工技术、营养成分及其对不同人群的影响研究进展. 食品安全质量检测学报. 2024(18): 123-130 .
10.	郭志伟，杨进洁，边文洁，赵祥忠，王晨莹. 酵母抽提物对植物蛋白肉品质的影响. 食品研究与开发. 2024(22): 9-14 .
11.	葛志优，王羽，高艳娥，蔡维. 植物蛋白肉超声振动3D打印方法与试验. 农业工程学报. 2024(20): 259-268 .
12.	王谊，陈志娜，尹琳琳，卞楠月，叶韬，陆剑锋. 豌豆蛋白粉添加量对低规格克氏原螯虾肉糜凝胶品质的影响. 廊坊师范学院学报(自然科学版). 2024(04): 56-62 .
13.	刘萌，王聪睿，刘波，赵祥忠. 豇豆血红蛋白Lb Ⅱ在大肠杆菌中的重组表达条件优化、纯化与鉴定. 食品工业科技. 2023(04): 163-170 . 本站查看
14.	樊炯，马骏骅，颜金鑫，张慧恩，杨华. 冷藏温度对植物基培根品质的影响. 食品与机械. 2023(05): 115-118+131 .
15.	孙莹，王龙，朱秀清，江连洲. 植物基蛋白肉的研究现状与挑战. 食品工业科技. 2023(17): 438-446 . 本站查看
16.	蔡维，王羽，高艳娥，李丽. 植物蛋白肉3D打印工艺参数优化. 农业工程学报. 2023(12): 254-264 .
17.	刘浩栋，张金闯，陈琼玲，张玉洁，李同庆，王强. 植物基肉制品营养品质研究现状. 中国食品学报. 2023(08): 428-439 .
18.	李振，相海，赵有斌，宋健宇，张德程，梁昊，张艺潇. 植物蛋白螺杆挤压组织化技术的研究进展. 中国油脂. 2023(09): 67-74 .
19.	陶相锦，黄立强，王冬玲，马文平，马世岷. 植物蛋白肉生产的关键因素分析. 食品安全导刊. 2023(30): 160-162 .
20.	佟宗航，李亚敏，高昂，谢赫然，高子凡，邢竹青. 植物蛋白肉产品品质评价及过敏原分析. 食品工业科技. 2022(04): 387-395 . 本站查看
21.	臧学丽，黄志远，叶春民. 高斯软件模拟转谷氨酰胺酶交联大豆分离蛋白机理的研究. 高分子通报. 2022(10): 108-119 .
22.	袁丽，孔云菲，贾世亮，石彤，励建荣，包玉龙，高瑞昌. 植物蛋白在动物肉糜类制品中的应用现状及研究进展. 肉类研究. 2022(10): 43-50 .
23.	豆康宁，赵永敢，金少举，李超敏，邓同兴，赵志军. 植物基肉制品的研究进展. 食品与机械. 2022(11): 230-235 .
24.	李家磊，管立军，高扬，严松，王崑仑，王春丽，李晓娟，卢淑雯，李波，周野. 液熏高水分挤压组织化植物蛋白加工工艺优化. 中国食品学报. 2022(11): 214-227 .
25.	高智利，杨军飞. 植物蛋白肉的研究进展与发展趋势. 食品安全导刊. 2021(12): 184-186 .
26.	周亚楠，王淑敏，马小清，缪松，卢旭. 植物基人造肉的营养特性与食用安全性. 食品安全质量检测学报. 2021(11): 4402-4410 .